NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Search Tool Menu
NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Menu
Close Button
Leadership


Jens Holstein

Jens Holstein has served on Veracyte’s board of directors since August 2020. Mr. Holstein has over 25 years of financial and management expertise, spanning an array of global life science businesses. He currently serves as Chief Financial Officer of BioNTech SE, an immunotherapy biopharmaceutical company based in Mainz, Germany.  Previously, Mr. Holstein was the Chief Financial Officer of MorphoSys, a clinical-stage biopharmaceutical company based in Munich, Germany, from 2011 to 2020. Before joining MorphoSys, Mr. Holstein worked at the pharmaceutical company Fresenius Kabi AG, a subsidiary of Fresenius SE, as Regional Chief Financial Officer for the Europe/Middle East Region and as Managing Director of Fresenius Kabi Deutschland GmbH. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein held multiple other leadership positions within the Fresenius SE Group including Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects and Service business unit of Fresenius, and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry. He has previously served as a director of InflaRx N.V., a biopharmaceutical company, from September 2018 to July 2020. He holds a Diploma in Business Administration from the University of Münster (Germany).